Global Orthobiologics Market By Type (Viscosupplementation, Synthetic Biologics, Bone Growth Factors, Demineralized Bone Matrix, and Others), By Applications (Spinal Fusion, Maxillofacial and Dental, Soft Tissue Repair, and Fracture Surgery), By End User, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2024-2033

Report Overview

The Global Orthobiologics Market size is expected to be worth around USD 14.2 Billion by 2033 from USD 7.9 Billion in 2023, growing at a CAGR of 6% during the forecast period from 2024 to 2033.

Orthobiologics are also called regenerative cell therapies. Orthobiologics contain growth factors that stimulate tissue healing, relieve pain, and restore normal function. There are many types of orthobiologics. Each type has a different mechanism of action. An autologous comes from the patient’s body and can be divided to form precursor cells under the right conditions. Orthobiologics can use them to treat conditions such as broken bones or fracture recovery and spinal fusion. They are also available in the hip, knee, ankle, and spine wrist.

Orthobiologics are primarily used to speed up the healing process of injuries. The ortho biologics market growth is obtained due to the rising number of geriatrics worldwide who are more susceptible to osteoarthritis. The market will expand due to increased awareness and demand for advanced treatments. The growth of the orthobiologics market is also attributed to the rise in obesity, road accidents, and sports injuries.

Key Takeaways

• Market Growth Projection: The global Orthobiologics Market is anticipated to reach approximately USD 14.2 Billion by 2033, showing significant growth from USD 7.9 Billion in 2023, with a projected CAGR of 6% during the period from 2024 to 2033.
• Type Analysis: Viscosupplement hold 61.4% market share in orthobiologics market in the type segment.
• Application Analysis: The spinal fusion segment dominates 72.9% market share the global market.
• End-user Analysis: Market 76.7% share dominance is due to the increasing use of orthobiologics in various reconstructive and spinal procedures performed in hospitals and ambulatory care centers.
• Regional Analysis: North America’s market accounts 32.6% market share and held USD 2.5 billion market revenue by 2023.
• Orthobiologics Defined: Orthobiologics, also known as regenerative cell therapies, encompass a range of products containing growth factors that stimulate tissue healing, relieve pain, and restore normal function. They are used in various medical applications.
• Driving Factors: The growth of the orthobiologics market is driven by an aging population, increasing orthopedic injuries, and a rising demand for advanced treatments. Orthobiologics reduce the need for pain medication and facilitate quicker healing.

Driving Factors

Growing Cases of Orthopedic Injuries to Enhance Market Growth

The growing number of senior individuals, as well as the subsequent growth in the occurrence of knee osteoarthritis, are the main reasons driving market dispersion. Orthobiologics raises the therapies of organic or natural composition form in the human body to treat musculoskeletal issues such as muscle injuries and ligament, bone fractures, and chronic illnesses such as osteoarthritis. Orthobiologic treatments can reduce the need for pain medication, speed up healing and improve rehabilitation.

They are a viable alternative to surgery. Orthobiologics is a treatment that helps professional and amateur athletes quickly recover from injuries. The demand for orthobiologics is positively impacted by rising interest in sports injury and physical injury. Degenerative changes can cause tendon tears in older people. Orthobiologics is seeing a boom in demand due to this and the aging population.

Restraining Factors

Issues Associated with Bone Morphogenetic Protein and Clinical Limitations of Several Orthobiologics to Limit the Market Growth

Medtronic INFUSE, the only bone-morphogenic protein on the market, is the only one. This product has been subject to significant scrutiny after receiving approval from the Food and Drug Administration. It is used in the Spinal Fusion procedure. Medtronic’s bone morphogenic protein has come under scrutiny since its approval by INFUSE several years ago.

This scrutiny stems from off-label INFUSE use and serious complications associated with these products. There are some limitations to the Bone Graft substitute. Market growth is expected to be limited by adverse tissue reactions, insufficient or absent bone formation, and infection of soft tissues and bone. The market’s expansion will be restricted due to the rising cost of orthobiologics-based therapies over the forecast period. The negative effects of Bone Morphogenic Protein-based treatments may hinder the industry’s rapid expansion.

Growth Opportunities

The Increase in Healthcare Expenditure Leads to Industry in Orthobiologics Market

Due to the growth of healthcare industries in emerging countries such as South Africa, India, South Africa, and China, Orthobiologics is seeing a boom. These countries must improve their healthcare industry due to the rapidly growing geriatric population, increasing per capita incomes, high patient numbers, and increased awareness. These economies have increased their investment in healthcare infrastructure and facilities.

Due to the high effectiveness of sleep apnea machines, they only work in a small percentage of cases due to their dependence on consistent use and medical supervision. Owing to the high number of applications of sleep apnea devices in healthcare industries, the rising investment in this industry is slated to offer growth opportunities in the market.

Trending Factors

Osteoarthritis and Degenerative Arthritis segment is expected to Experience the Fastest Growth in the Market

Osteoarthritis can affect any joint of the body and is very common. Osteoarthritis is most common in the joints that support most of our body weight, like the knees and feet. Additionally, it can affect the joints that are used daily, like the hands. Market growth will be further driven by factors like the rising incidence of osteoarthritis, increasing geriatric populations, increased product launches, and strategic initiatives taken by market leaders.

Type Analysis

Due to the Increase in Adaption, viscosupplements Can Dominate the Global Market Growth 

On the basis of product type, orthobiologics are divided into Viscosupplements and bone growth factors, artificial biologics, demineralized bone matrix, and others. Viscosupplement hold 61.4% market share in orthobiologics market in the type segment. This is primarily due to the rising incidence of degenerative arthritis and knee osteoarthritis, especially among the aging population. This segment is supported by the approval of viscosupplements and an increase in reimbursement policies.

The Recent Market approval and new manufacturers also support this segment. The segment of synthetic bone substituted is expected to grow at the highest CAGR over the forecast period. The highest segmental growth can be attributed to the synthetic adaptation of synthetic bone graft, which is found in developed geographical like the U.S.A. and Europe. The gradual shift to synthetic bone graft replacements and manufacturers’ increasing focus on the launch of new products will boost segmental growth.

By Application Analysis

Spinal Fusion Segment to hold significant market share Due to a Large Number of Spinal Surgeries Perform

Based on application, the market is segmented into Spinal fusion, Maxillofacial and Dental, Soft Tissue Injuries, and Reconstructive and fracture Surgery. The spinal fusion segment dominates 72.9% market share the global market. The segments have large shares due to the increasing number of spinal fusion surgeries being performed globally.

The key companies with an extensive product portfolio of orthobiologics products for spinal fusion application area and increasing approvals for new products for spinal fusion procedures are expected to boost the segmental growth in the coming years. The reconstructive and fracture surgery segment held the second-largest market share. It is expected to grow at a moderate CAGR during the forecast period. Segmental growth is mainly due to increased fracture cases due to the prevalence of osteoporosis.

End-User Analysis

Hospitals and Ambulatory Surgical Centers Segment to Hold Significant Market Share Due to Large Patient Volume.

Based on the end-user market segment is divided into hospitals, ambulatory surgical centers, and specialty centers. Market 76.7% share dominance is due to the increasing use of orthobiologics in various reconstructive and spinal procedures performed in hospitals and ambulatory care centers. The segment growth will likely be fueled by specialist patient care and easy access to many orthobiologics in clinics. High patient turnover, frequent readmissions, and high-volume procedures also influenced segment share. This supportive infrastructure encourages the execution of precise procedures, which will increase growth potential.

Key Market Segments

Based on Type

• Viscosupplementation
• Synthetic Biologics
• Bone Growth Factors
• Demineralized Bone Matrix
• Other Product Types

Based on Application

• Spinal Fusion
• Maxillofacial and Dental
• Soft Tissue Repair
• Reconstructive and Fracture Surgery

Based on End-User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Other Users

Regional Analysis

North America Dominated Largest Shares in the Global Orthobiologics Market 

North America’s market accounts 32.6% market share and held USD 2.5 billion market revenue by the rising incidence of degenerative bone disease and the growing popularity of outpatient orthopedic procedures. North America is the dominant market due to its large number of major companies. The increasing age of the population will drive the projected growth of the market. Cingal has been granted a new marketing authorization. This allows for a viscosupplement to Europe. Europe will be the second largest market in terms of sales, with a significant market share. The market’s expansion in Asia Pacific is also due to an increase in research, development, and innovation activities and an increase in orthobiologics awareness.

The Asia Pacific market is also growing due to increased osteoarthritis, persistent arthritis, and orthopedic diseases. As physicians become more aware of orthobiologics, the market will grow. In the coming years, the market will expand due to rising healthcare spending and increasing disposable income. Asia Pacific is driven primarily by India’s increasing demand for viscosupplements and increased freestanding orthopedic clinics.

Key Regions and Countries Covered in this Report:

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Emerging key players are focused on various strategic policies to develop their respective businesses in foreign markets. Several orthobiologics market companies are concentrating on expanding their existing operations and R&D facilities. Furthermore, businesses in the orthobiologics market are developing new products and portfolio expansion strategies through investments, mergers, and acquisitions. In addition, several key players are now focusing on different marketing strategies, such as spreading awareness about natural ingredients, which is boosting the target products’ growth.

Market Key Players

With the presence of many local and regional players, the market for global orthobiologics is segmented. Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks. To stay on top of the market, companies have gained various expansion strategies such as partnerships and product launches.

Listed below are some of the most prominent Orthobiologics industry players.

• NuVasive Inc.
• Arthrex, Inc.
• Globus Medical, Inc.
• Bone Biologics, Corp.
• K2M Group Holdings, Inc.
• Orthofix Medical Inc.
• Bioventus Inc.
• Medtronic PLC
• DePuy Synthes, Inc.
• Bone Solutions Inc.
• Other Key Players

Recent Developments

• September 2023: Bone Biologics, Corp. Announced positive interim results from Phase 2 clinical trial of its stem cell therapy for osteoarthritis.
• October 2023: NuVasive Inc. Launched Simplify Disc Technology, a next-generation, interbody fusion device with simplified instrumentation.
• November 2023: Arthrex, Inc. Launched Eclipse Meniscal Repair System, a suture-based technique for meniscal repairs.
• December 2023: Globus Medical, Inc. Acquired Cellularity, Inc., a company developing stem cell therapies for musculoskeletal conditions.

Report Scope: